Clinical Trials
6 trialsNCT01780545 2022-07-11
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01120470 2019-02-15
OGX-427 in Castration Resistant Prostate Cancer Patients
British Columbia Cancer Agency
Phase 2 Completed
NCT01829113 2018-06-08
Spruce
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01844817 2017-05-16
Rainier
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01454089 2016-10-07
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Achieve Life Sciences
Phase 2 Completed
NCT00487786 2016-01-18
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
Achieve Life Sciences
Phase 1 Completed